



Published in final edited form as:

*J Addict Dis.* 2009 October ; 28(4): 309–319. doi:10.1080/10550880903182960.

## COMORBID MOOD, PSYCHOSIS, AND MARIJUANA ABUSE DISORDERS: A THEORETICAL REVIEW

Natascha Wilson, PhD and Jean Lud Cadet, MD\*

National Institute of Health, National Institute on Drug Abuse, Intramural Research Program,  
Molecular Neuropsychiatry Branch, Baltimore, MD 21224

### Abstract

There is a need to bridge the gap between the fields of addiction psychiatry and general psychiatry in order to effectively treat co-morbid substance abuse and psychiatric disorders. This alarming epidemic transcends communities and severely impacts healthcare worldwide yielding poor treatment outcomes and prognoses for afflicted patients. Because substance abuse can exacerbate and/or trigger psychosis and mood disorders, it is important to keep these issues in the forefront when evaluating patients. In order to address some of the complications stemming from not enough interactions between various groups of practitioners, this review addresses the neurobehavioral effects of cannabis use and their impact on patients who suffer from psychotic or affective disorders. The hope is that this paper will serve as a spring board for further discussions among practitioners who treat these patients. Greater interactions between caretakers are bound to impact the care of our patients in a very positive way.

### GENERAL INTRODUCTION

Substance abuse and dependence pose major clinical and public health concerns among psychiatric patients. Although epidemiological studies have documented the prevalence of co-morbid diagnoses in the general population, medical professionals and society remain ill-equipped to manage these problems. These issues are compounded by the high cost of treatment and relapse rates observed in patients. Fundamentally, an approach integrating pharmacologic, psychosocial and psychotherapy is ideal; however, only recently have scientists begun to focus attention on the neurobiological underpinnings of co-morbidity. It has been reported that patients who suffer from either psychiatric diathesis or substance abuse disorders also show cognitive impairments which are associated with brain functional and morphological abnormalities. The aim of this paper is to review the clinical neuropsychiatric underpinnings of the co-morbidity of marijuana abuse, affective and psychotic disorders. This background is used to provide a theoretical framework from which to address the treatment of these co-morbid states.

### CANNABIS ABUSE

#### Introduction

Marijuana is the most prevalently used illicit substance with a minority of users indicating daily use and dependency.<sup>1</sup> In fact, 1.6 million marijuana users met the criteria for substance dependency according to the Diagnostic and Statistical Manual for Mental Disorders (DSM)-IV in 2000.<sup>2-4</sup> Marijuana dependence, like other substance dependence disorders, is

\*Address Correspondence to: Jean Lud Cadet, MD National Institute on Drug Abuse, Intramural Research Program, National Institute on Health, Department of Health and Human Services, NIH Biomedical Research Center at Bayview, 251 Bayview Blvd., Baltimore, MD 21224, USA Phone: 443- 740-2656 Fax: 443-740-2856 Email: jcadet@intra.nida.nih.gov.

associated with cognitive, behavioral and physiological effects including the cannabis withdrawal syndrome.<sup>4-7</sup> The clinical effects of marijuana are due to the active ingredient,  $\Delta^9$  tetrahydrocannabinol (THC), contained in marijuana.<sup>8, 5</sup> THC mimics the action of natural cannabinoids that the body produces and binds to cannabinoid receptors, CB<sub>1</sub> and CB<sub>2</sub>, namely CB<sub>1</sub>.<sup>9</sup> CB<sub>1</sub> and CB<sub>2</sub> are found in several brain regions including the frontal cortex, striatum, and hippocampus.<sup>10, 11-12</sup> The localization of these receptors might account for the clinical presentation of marijuana abuse. Neuroanatomical findings show, that CB<sub>1</sub> interacts with dopamine (DA), specifically D<sub>2</sub>, coexist in several brain regions and that CB<sub>1</sub> modulates the function of dopamine.<sup>13-16</sup> This interaction manipulates motor activity, endocrine regulation, appetite, learning, memory, cognition, mood and pain perception.<sup>17-18</sup> However, the underlying molecular mechanisms of cannabinoid and dopaminergic interaction remains poorly understood.

### Clinical Neuropsychiatry

Until recently, marijuana use was considered harmless and generally associated with feelings of euphoria, detachment and relaxation.<sup>19</sup> However, the accumulated evidence suggests that chronic marijuana users experience acute adverse mental effects<sup>4-7 19</sup> with a range of short lived signs and symptoms which include depersonalization, derealization, irrational panic and paranoia, as well as feelings of loss of control and fear of dying.<sup>20</sup> While many of these adverse are usually transient, they tend to persist or recur among regular users.<sup>20</sup> Additional adverse effects include cannabis psychosis,<sup>21</sup> amotivational syndrome,<sup>22</sup> as well as cannabis withdrawal syndrome which consists of anxiety, irritability, physical symptoms and decreased appetite/weight loss.<sup>23</sup> Such withdrawal symptoms have been noted in several treatment projects.<sup>24-28</sup>

### Cognitive Effects

Imaging data correlating cognitive performance with marijuana show decreased cerebral blood flow in the auditory cortex and left superior temporal gyrus regions on task of dichotic listening for meaningless syllables in subjects with a history of moderate use.<sup>29</sup> On a visual attention paradigm, decreased activation in the right prefrontal, medial, dorsal parietal cortices and medial vermis of the cerebellum were detected in both abstaining and active marijuana users when compared to controls.<sup>30</sup> Additional data show that marijuana use is associated with subtle cognitive impairments and the activation of the frontal lobe, dorsolateral prefrontal cortex and the hippocampus which are brain regions linked to executive function, working memory and manual dexterity.<sup>31-35</sup> Conversely, data exists that show no cognitive deficits associated with marijuana use. For example, Jager et al.,<sup>36</sup> found no evidence of working memory or selective attention deficits among cannabis users during one week of abstinence. In fact, no significant differences on tasks of visuo-auditory and verbal working memory were observed between users and non-users.<sup>36</sup> Moreover, research is uncertain regarding the long-term cognitive effects of marijuana use. For instance, some studies show no recovery after a month of abstinence,<sup>35, 37-38</sup> whereas others report full recovery<sup>39</sup> or show partial recovery.<sup>40</sup>

### Neuroimaging Studies

CB<sub>1</sub> receptors are distributed heterogeneously in the CNS<sup>41</sup> with elevated concentrations found in the neocortex, thalamic nuclei, limbic regions, basal ganglia and cerebellar cortex.<sup>10</sup> Thus by activating the presynaptic cannabinoid receptor CB<sub>1</sub>, a spectrum of functions are manipulated.<sup>17-18</sup> Global cortical effects of marijuana have been documented including global cerebral glucose metabolism after infusion of THC,<sup>42</sup> increased cerebral blood flow in frontal regions with greater increases detected in the right hemisphere among individuals reporting a history of use,<sup>43</sup> lower volumes of ventricular cerebrospinal fluid (CSF) among users when compared to controls,<sup>44</sup> denser grey matter in the parahippocampal gyrus and

denser white matter in the left parietal lobe among heavy users compared to non-users<sup>45</sup> as well as elevated systolic and mean blood flow velocity in the middle cerebral artery (MCA), anterior cerebral artery (ACA) and higher pulsatility index (PI) in both the MCA and ACA.<sup>46</sup>

## **BIPOLAR DISORDER**

### **Introduction**

Bipolar disorder is a chronic psychiatric condition with 2% of Canadians and 3% of Americans meeting formal criteria for the disorder.<sup>47-48</sup> Current estimates of lifetime prevalence of bipolar disorder range from 3% to 6.5%. Prevalence rates are higher among women, individuals with comorbid neurological conditions, and adults who are separated, divorced or widowed.<sup>49</sup> This disease is often associated with premature mortality,<sup>50</sup> profound functional impairments<sup>51</sup> and substantial treatment cost.<sup>52</sup> However, with proper treatment and diagnosis, bipolar patients are more likely to adhere to medication regimens, respond to short term treatment and experience fewer relapse episodes.<sup>53</sup>

### **Clinical Neuropsychiatry**

Bipolar disorder is characterized by recurrent episodes of acute mania, depression and mixed emotions. Depressive signs include unintentional weight loss or weight gain, insomnia or hypersomnia, psychomotor agitation or retardation, loss of feelings of worthlessness or excessive guilt, impaired concentration or indecisiveness and recurrent thoughts of death or suicide ideation.<sup>6</sup> Manic signs include inflated self-esteem, decreased need for sleep, talkative or pressured speech, flight of ideas, distractibility, psychomotor agitation and increased probability of risking behaviors resulting in pain.<sup>6</sup> Typically manifesting during late adolescence or early adulthood, bipolar disorder is often triggered by stress.

### **Cognitive Effects**

Cognitive deficits in bipolar patients include psychomotor slowing, memory and concentration impairments.<sup>54</sup> These patients also have difficulties encoding information on verbal learning tasks.<sup>55</sup> On sustaining attentional measures bipolar patients performed poorer and made more errors of omission than unipolar patients.<sup>56</sup> Additional differences have also been observed among the various episodic states. For example, visuospatial deficits as well as other cognitive impairments observed among bipolar patients have been attributed to mood state.<sup>57</sup> However, research is unable to consistently link cognitive deficits to state factors in bipolar patients.<sup>58</sup>

### **Neuroimaging Studies**

Abnormalities in the anterior limbic networks including the dorsolateral prefrontal cortex, anterior cingulate, amygdala, hippocampus, striatal enlargement, cerebellar atrophy as well as ventriculomegaly have been reported in the brains of patients who suffer from bipolar disorder.<sup>59-61</sup> Smaller subgenual prefrontal cortex (SGPFC) has been reported in bipolar patients with a family history of affective illness.<sup>62</sup> This region works in concert with cingulated and other anterior limbic regions to perform integration of cognitive and emotional information integration.<sup>62</sup> Functional imaging data show regional hyper-fusion in left frontal and temporal lobes<sup>63</sup> as well as increased metabolism. Perfusion in temporal structures and prefrontal cortex have been documented in patients functioning in various episodic states.<sup>64-65</sup> Recently, Agarwal et al<sup>63</sup> have reported that bipolar patients show inverse frontal asymmetry index.

## SCHIZOPHRENIC DISORDER

### Introduction

Schizophrenia is a complex disorder affecting nearly 1.1 percent of Americans a year.<sup>66</sup> It is among the most expensive diagnosis in medicine accounting for 2.5% of US healthcare expenditure.<sup>67-68</sup> Per patient, treatment has been estimated to cost \$25,940 annually with majority of monies allocated for nursing home care while the residual expenditure funds ambulatory services, psychotherapy, acute hospital care, prescription drugs and psychiatric hospital care.<sup>69</sup> In fact, schizophrenic patients occupy 20-25% of available beds in psychiatric hospitals.<sup>68</sup> The dopaminergic hypothesis implicates the dopaminergic system in the pathophysiology of schizophrenia.<sup>69</sup> Currently, the schizophrenia disorder paradigm speculates that the mesolimbic, mesocortical and nigrostriatal dopamine (DA) neurons are slightly overactive thus increasing delusional and hallucinating symptoms and various cognitive deficits in schizophrenic patients.<sup>70</sup>

### Clinical Neuropsychiatry

Schizophrenia disorder usually manifests during late adolescence and young adulthood. Clinical signs and symptoms are categorized as either positive or negative. Positive symptoms encompass auditory hallucinations, delusions, disorganization of speech, and movement disorders whereas negative symptoms encompass flat affect, poverty of speech and other deficits.<sup>6</sup> Negative symptoms are often misinterpreted as laziness or depression.<sup>66</sup> In severe cases, the disease fuels the most basic functions and allows the individual to feel quintessential possessing irrational beliefs without any basis in reality.<sup>71</sup> Given this, many schizophrenic patients experience adverse social and emotional consequences.

### Cognitive Effects

Studies have identified cognitive deficits with language comprehension, learning and reasoning judgment,<sup>72-74</sup> on visuospatial paradigms,<sup>75</sup> attention, concentration, set shifting, planning, and anticipation as well as concept formation in schizophrenic patients.<sup>76-79</sup> Additional studies have linked performance deficits to disorganization syndrome in schizophrenic patients on task of cognitive deficits with shifting set and interference tasks.<sup>80-82</sup> Syndrome dimensions reflecting psychomotor deficits have been linked to verbal fluency and memory measures.<sup>81, 83-85</sup> O'Leary et al<sup>86</sup> showed a relationship between cognitive deficits and disorganization and negative syndrome. However, the patterns of negative syndrome were significantly different from patterns of disorganization syndrome which suggest different neurobiological substrates between the two dimensions.<sup>86</sup> When correlating cognitive performance on executive functioning tasks and cerebral blood flow, data show lower cerebral blood flow in the prefrontal regions on Wisconsin Card Sorting Task (WCST),<sup>87</sup> lower frontal activation Tower of London,<sup>88</sup> as well as alterations in mean flow velocity in schizophrenic patients during WCST,<sup>89-91</sup> Tower of Hanoi<sup>89</sup> and Stockings of Cambridge.<sup>92</sup>

### Neuroimaging Studies

While converging neuroanatomical evidence suggests major morphological brain abnormalities in the temporal lobes,<sup>93</sup> other studies implicate the enlargement of lateral ventricles,<sup>94</sup> reduction in prefrontal lobe volumes,<sup>93</sup> altered inferior parietal cortex, basal ganglia, thalamus, corpus callosum or enlargement of septum pellucidum<sup>95-96</sup> as well as reduced cortical folding and loss of normal asymmetry.<sup>95</sup> While the nature of the underlying mechanism involved in the pathophysiology is unclear, evidences suggest neurodevelopmental lesions resulting in brain abnormalities, neurodevelopmental abnormalities interacting with biochemical factors such as HPA dysregulation,<sup>97</sup> adverse

effects of stress,<sup>98</sup> poor diet and exercise,<sup>97</sup> as well as brain alterations attributed to antipsychotic extrapyramidal effects.<sup>99</sup> Additional neuroimaging studies show left dominance hyperperfusion in both the middle and anterior cerebral arteries in acute schizophrenics,<sup>99</sup> and increased in global cerebral perfusion when compared to controls,<sup>100</sup> increased cerebral blood flow volume in first episode acute schizophrenics<sup>101</sup> as well as impairment of frontal regional CBF or regional glucose metabolism when compared to controls.<sup>102-104</sup> Abnormal regional CBF have also been reported in the temporal lobes<sup>99</sup> and while some report increased metabolism in the basal ganglia,<sup>102, 104</sup> others report no difference.<sup>99, 105</sup>

## COMORBIDITY OF MARIJUANA ABUSE AND PSYCHIATRIC DISORDERS

### Introduction

The prevalence of substance abuse among individuals with pervasive psychiatric diagnosis is an increasing concern.<sup>106-108</sup> In the US alone, nearly 47% of schizophrenic and 61% of bipolar patients report higher rates of substance abuse than the general public.<sup>109</sup> Among individuals living with a psychiatric diagnosis or at risk for developing a psychiatric diagnosis, a spectrum of negative symptoms are generally associated with illicit drug use.<sup>110</sup> Moreover, evidence suggest increasing mortality rates among co-morbid patients associated with obesity, cardiovascular and respiratory issues.<sup>111-114</sup> Comorbidity is associated with poor treatment compliance, higher rates of drug relapse, violent behaviors, unstable housing and homelessness.<sup>115-118</sup> Thus, developing reliable and accurate methods of assessing and treating comorbidity is critical when developing effective paradigms for patient care.

### Clinical Neuropsychiatry

Data suggests a kindred relationship between neurologic conditions and substance abuse, more specifically the cannabinoid system.<sup>119-120</sup> In fact, the endogenous cannabinoid system modulates the dopaminergic system which is involved with the networks regulating motor control, emotional response and cognitive processes in schizophrenia disorder<sup>121-122</sup> as well as characteristics of depression.<sup>123</sup> Comorbidity is associated with increased suicidal risks,<sup>124</sup> impulsive or aggressive behaviors<sup>125</sup> as well as poor clinical prognosis<sup>126</sup> with marijuana use exacerbating psychopathology in both schizophrenia and bipolar disorder.<sup>127-128</sup> However, depressed patients report using marijuana to reduce duration of depression<sup>129</sup> and counteract adverse antidepressant effects.<sup>130-131</sup> Schizophrenic patients report using marijuana to “self-medicate” extrapyramidal effects of neuroleptics as well as to relax, feel good and stimulate social interaction.<sup>132-135</sup> These explanations for “self-medicating” are extremely subjective, biased and rely on self-reports, which is ironic because denial and rationalization both play a crucial role in drug abuse.<sup>136-137</sup>

### Cognitive Effects

Liraud and Verdoux<sup>138</sup> concluded that comorbid marijuana use and psychotic or mood disorders compromised cognitive functioning on a test of inhibition. Pencer and Addington<sup>139</sup> found during a 1 year follow up that marijuana use correlated with poor performance on category naming among first psychotic episodic patients. Conversely, first psychotic episode patients with a history of marijuana use outperformed non-using first psychotic episode patients on task measuring memory, verbal fluency, visual spatial construction, sequencing and facial recognition<sup>140-141</sup> as well as on tasks of emotion-based decision making.<sup>142</sup> Although marijuana use in bipolar patients has not been extensively researched, it is believed that marijuana use would exacerbate cognitive deficits.<sup>143</sup>

## Neuroimaging Studies

Studies show less anterior grey matter in first episode schizophrenic patients who used marijuana when compared to non-using and healthy controls.<sup>144</sup> More prominent gray matter density as well as volume reduction in the right posterior cingulate cortex have been reported in first episode schizophrenics who used marijuana when compared to controls and marijuana naïve schizophrenic patients.<sup>145</sup> Pronounced reduced brain volume over a 5-year follow-up have been reported in marijuana using schizophrenic patients compared to their non-using counterparts.<sup>146</sup> Higher serum of nerve growth factor have also been reported in schizophrenic patients who used marijuana compared to non-using schizophrenic patients.<sup>147</sup>

Marijuana use increases the risk of developing schizophrenia disorder or depressive mood disorders later in life.<sup>148-149</sup> Given this, age of initial use may be critical in understanding structural abnormalities in comorbid patients. However, this possible relationship between early use and diagnosis poses obstacles when determining whether functional abnormalities in comorbid adults should be attributed to substance use or to biological predisposition of the psychiatric disorders. Additionally, to generalize adolescent findings to adult, researchers must consider adolescent neuromaturation. Nonetheless, it does offer some insight regarding the psychiatric associated structural abnormalities possibly exacerbated by marijuana use.

## CONCLUSION

Over the past two decades, a high prevalence of marijuana use has been reported among individuals suffering with psychotic and affective disorders. This review of the literature on co-morbid diagnoses reveals that these are problems with elucidating the relationship between psychiatric disorders and substance abuse, applying DSM-IV guidelines for diagnosing co-morbid disorders and pharmacological approaches to the treatment of these disorders.<sup>150-152</sup> Despite substantial research gathered on co-morbid diagnoses, much remains to be done in order to understand the neuropathological substrates of these disorders. Because experts from various fields have not come together, it has been somewhat difficult to understand the initial impact that marijuana use might have on affective and schizophrenic disorders. For example, how does marijuana exacerbate clinical symptoms like psychosis and depression? Are these related to cannabis-induced compromise neurobehavioral performances, cerebral perfusion and electrophysiological alterations.<sup>153-154</sup> Unfortunately, there is very little written on the underlying mechanisms that contribute to the functional impairments of patients with comorbid diagnoses. Possibly, this gap has a lot to do with bridging diagnoses and treatment effectiveness. Thus, allocating more research funds to this major public health issue will heighten awareness and potentially, revolutionize the care of these patients.

## Acknowledgments

This research is supported by the DHHS/NIH/NIDA Intramural Research program.

## REFERENCES

1. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration Office of Applied Studies, NHSDA Series H-21, DHHS Publication No. SMA03-3774. Rockville, MD: 2002. Overview of Findings from the 2002 National Survey on Drug Use and Health.
2. Epstein, JF. Substance Dependence, Abuse and Treatment: findings from the 2000 National Household Survey on Drug Abuse. NHSDA Series A-16, DHHS Publication no. SMA 02-3642.

- Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2002. <http://www.DrugAbuseStatistics.SAMSHA.gov>
3. Iversen L. Long-term effects of exposure to cannabis. *Curr Opin Pharmacol* 2005;5:69–72. [PubMed: 15661628]
  4. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 2006;19:233–238. [PubMed: 16612207]
  5. Budney AJ, Moore BA. Development and consequences of cannabis dependence. *J Clin Pharmacol* 2002;42:28S–33S. [PubMed: 12412833]
  6. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed.. American Psychiatric Association; Washington, DC: 1994.
  7. World Health Organization. *ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines*. World Health Organization; Geneva, Switzerland: 1992.
  8. Lichtman AH, Martin BR. Marijuana withdrawal syndrome in the animal model. *J Clin Pharmacol* 2002;42:20S–27S. [PubMed: 12412832]
  9. Basavarajappa BS. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. *Curr Neuropharmacol* 2007;5(2):81–97. [PubMed: 18084639]
  10. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience* 1997;77(2):299–318. [PubMed: 9472392]
  11. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* 2002;54(2):161–202. [PubMed: 12037135]
  12. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. *AAPSJ* 2005;7:EE625–654.
  13. D'Souza DC, Braley G, Blasie R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of  $\Delta$ -9-tetrahydrocannabinol in humans. *Psychopharmacology* 2008;198(4):587–603. [PubMed: 18228005]
  14. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. *Pharmacol Biochem Behav* 2005;81(2):263–284. [PubMed: 15936806]
  15. Laviolette SR, Grace AA. Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdale inputs. *J Neurosci* 2006;26(24):6458–6468. [PubMed: 16775133]
  16. Herman H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. *Neuroscience* 2002;109(3):451–460. [PubMed: 11823058]
  17. Maccarrone M, Wenger T. Effects of cannabinoids on hypothalamic and reproductive function. *Handb Exp Pharmacol* 2005;168:555–571. [PubMed: 16596787]
  18. Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. *Neurobiology of Diseases* 1998;5:417–431.
  19. Johns A. Psychiatric effects of cannabis. *Br Journal of Psychiatry* 2001;178:116–122.
  20. Thomas H. Psychiatric symptoms in cannabis users. *Br Journal of Psychiatry* 1993;163:141–149.
  21. Thacore VR, Shukla SRP. Cannabis psychosis and paranoid schizophrenia. *Arch Gen Psychiatry* 1976;383–386. [PubMed: 1259526]
  22. Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. *Arch Gen Psychiatry* 1972;27:133–136. [PubMed: 5032722]
  23. Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. *Exp Clin Psychopharmacol* 2000;8:483–492. [PubMed: 11127420]
  24. Crowley TJ, MacDonald MJ, Whitmore EA, Mikulich SK. Cannabis dependence, withdrawal and reinforcing effects among adolescents with conduct disorder symptoms and substance use disorders. *Drug Alcohol Depend* 1998;50:27–37. [PubMed: 9589270]

25. Mikulich SK, Hall SK, Whitmore EA, Crowley TJ. Concordance between DSM-III R and DSM-IV diagnoses of substance use disorders in adolescents. *Drug Alcohol Depend* 2001;61(3):237–248. [PubMed: 11164688]
26. Budney AJ, Radonovich KJ, Higgins ST, Wong CJ. Adults seeking treatment for marijuana dependence: a comparison with cocaine-dependent treatment seekers. *Exp Clin Psychopharmacol* 1998;6(4):419–426. [PubMed: 9861556]
27. Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. *J Subst Abuse Treat* 2001;21(2):55–64. [PubMed: 11551733]
28. Stephens RS, Babor TF, Kadden R, Miller M. The marijuana treatment project: rationale, design and participant characteristics. *Addiction* 2002;97:109–124. [PubMed: 12460133]
29. O'Leary DS, Block RI, Flaum M, Schultz SK, Ponto LLB, Watkins GL, Hurtig RR, Andreasen NC, Hichwa RD. Acute marijuana effects on rCBF and cognition: a PET study. *NeuroReport* 2000;11(17):3835–3841. [PubMed: 11117500]
30. Chang L, Yakupov R, Cloak C, Ernst T. Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. *Brain* 2006;129:1096–1112. [PubMed: 16585053]
31. Hart, C.; McCance-Katz, EF.; Kosten, TR. Pharmacotherapies used in common substance use disorders. In: Tims, FM.; Leukefeld, CG.; Platt, JJ., editors. *Relapse and Recovery in Addictions*. Yale University Press; New Haven: 2001. p. 303-333.
32. Block RI, O'Leary DS, Hichwa RD, Augustinack JC, Ponto LLB, Ghoneim MM, Arndt S, Hurtig RR, Watkins GL, Hall JA, Nathan PE, Andreasen NC. Effects of frequent marijuana use on memory-related regional cerebral blood flow. *Pharmacol Biochem Behav* 2002;72:237–250. [PubMed: 11900794]
33. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. *Neuroimaging* 2004;23:914–920.
34. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. *Neurology* 2000;59(9):1337–1343. [PubMed: 12427880]
35. Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. *NeuroImage* 2005;26:480–492. [PubMed: 15907305]
36. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. *Psychopharmacology* 2006;185(3):358–368. [PubMed: 16521034]
37. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. *Neurology* 2002;59:1337–1343. [PubMed: 12427880]
38. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. *Neuroimaging* 2004;23:914–920.
39. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. *Arch Gen Psychiatry* 2001;25:909–915. [PubMed: 11576028]
40. Solowij, N. *Cannabis and cognitive functioning*. Cambridge University Press; Cambridge: 1998.
41. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. *Int J of Obesity* 2006;30:S13–S18.
42. Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Ivanovic M, Hollister L. Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-dexoyglucous. *Psychiatry Res Neuroimaging* 1991;40(1):69–78.
43. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE. Regional cerebral blood flow after marijuana smoking. *J Cereb Blood Flow Metab* 1992;12(5):750–758. [PubMed: 1324250]
44. Block RI, O'Leary DS, Erhardt JC, Augustinack JC, Ghoneim MM, Arndt S, Hall JA. Effects of frequent marijuana use on brain tissue volume and composition. *Neuroreport* 2000;11(3):491–496. [PubMed: 10718301]
45. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy marijuana users. *Drug and Alcohol Dependence* 2005;77(1):23–30. [PubMed: 15607838]



46. Herning RI, Better WE, Tate K, Cadet JL. Cerebrovascular perfusion in marijuana users during month of monitored abstinence. *Neurology* 2005;64:488–493. [PubMed: 15699380]
47. Schaffer A, Cairney J, Cheung A, Veldhuizen S, Levitt A. Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. *Can J Psychiatry* 2006;51:9–16. [PubMed: 16491979]
48. Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, Huang B. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2005;66:1205–1215. [PubMed: 16259532]
49. Kessler RC, Burglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 2003;289:3095–3105. [PubMed: 12813115]
50. Balázs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. *J of Affective Disorders* 2006;91:133–138.
51. Murphy FC, Sahakian BJ. Neuropsychology of bipolar disorder. *BR J Psychiatry* 2001;178:120–127.
52. Fountoulakis NK, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, Fresno D, Giannakopoulos P, Kaprinis GS. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. *Annals of General Psychiatry* 2007;6:27. [PubMed: 17925035]
53. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. *CNS Drugs* 2007;21(11):911–936. [PubMed: 17927296]
54. Wolfe J, Granholm E, Butters N, Sanders E, Janowsky D. Verbal memory deficits associated with major affective disorders: A comparison of unipolar and bipolar patients. *J Affect Disord* 1987;13:83–92. [PubMed: 2959704]
55. Calev A, Nigal D, Chazan S. Retrieval from semantic memory using meaningful and meaningless constructs by depressed, stable bipolar and manic patients. *Br J Clin Psychology* 1989;28(1):67–73.
56. Sweeney JA, Kmiec JA, Kupfer DJ. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. *Biol Psychiatry* 2000;48(7):674–684. [PubMed: 11032979]
57. Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D, Kleinman JE, Weinberger DR. Contrasts between patients with affective disorders and patients with schizophrenia on neuropsychological test battery. *Am J Psychiatry* 1993;150:1355–1362. [PubMed: 8352346]
58. van Gorp WG, Althuler L, Theberge DC, Wilkins J, Dixon W. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. *Arch Gen Psychiatry* 1998;55:41–46. [PubMed: 9435759]
59. Strawkowski SM, DelBello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. *Mol Psychiatry* 2005;10:105–116. [PubMed: 15340357]
60. Campbell S, MacQueen G. An update on regional brain volume differences associated with mood disorders. *Curr Opin in Psychiatry* 2006;19:25–33.
61. Hwang J, Lyoo IK, Dager ST, Friedman SD, Oh JS, Lee JY, Kim SJ, Dunner DL, Renshaw PF. Basal ganglia shape alterations in bipolar disorder. *Am J Psychiatry* 2006;163:276–285. [PubMed: 16449482]
62. Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. *Nature* 1997;386(6627):824–827. [PubMed: 9126739]
63. Agarwal N, Bellani M, Perlini C, Rambaldelli G, Atzori M, Cerini R, Vecchiato F, Pozzi Mucelli R, Andreone N, Balestrieri M, Tansella M, Brambilla P. Increased fronto-temporal perfusion in bipolar disorder. *J of Affective Disorder* 2008;110:106–114.
64. Blumberg HP, Stern E, Martinez D, Ricketts S, de Asis J, White T, Epstein J, McBride PA, Eidelberg D, Kocsis JH, Silbersweig DA. Increased anterior cingulate and caudate activity in bipolar mania. *Biol Psychiatry* 2000;48(11):1045–1052. [PubMed: 11094137]

65. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdale in depression: relationship to diagnostic subtype and plasma cortisol levels. *Pharmacol Biochem Behav* 2002;71(3):431–447. [PubMed: 11830178]
66. National Institution of Mental Health. Schizophrenia: with addendum schizophrenia. Author; Rockville, MD: Jan. 2007 NIH Publication No. 06-3517
67. Gold JM, Weinberger DR. Cognitive deficits and the neurobiology of schizophrenia. *Curr Opin in Neuro* 1995;5:225–230.
68. Bernard M, Ramón AJ, Rubio-Terrés C, Rejas J. Cost-effective analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. *Clin Drug Investig* 2006;26(8):447–457.
69. McCombs JS, Nichol MB, Johnstone BM, Stimmel GL, Shi J, Smith R. Antipsychotic drug use pattern and the cost of treating schizophrenia. *Psychiatr Serv* 2000;51(4):525–527. [PubMed: 10737831]
69. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. *Neuropsychopharmacology* 1988;1:179–186. [PubMed: 3075131]
70. Metzger HY. Biological studies in schizophrenia. *Schizophr Bull* 1987;13(1):77–111. [PubMed: 3602940]
71. Kuipers, E.; Peters, E.; Bebbington, P. Schizophrenia. In: Carr, A.; McNulty, M., editors. *The Handbook of Adult Clinical Psychology: An evidence-based practice approach*. Taylor and Francis Group; New York: 2006. p. 843-896.
72. Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, Frank JA, Pickar D, Weinberger DR. The relationship between dorsolateral prefrontal neuronal n-acetylaspartate and evoked release of striatal dopamine in schizophrenia. *Neuropsychopharmacology* 2000;22(2):125–132. [PubMed: 10649825]
73. Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. *Acta Psychiatr Scand Suppl* 2000;400:11–16. [PubMed: 10823306]
74. Bradley A. Working memory. *Science* 1992;255:556–559. [PubMed: 1736359]
75. Fleming K, Goldberg TE, Blinks S, Randolph C, Gold JM, Weinberger DR. Visuospatial working memory in patients with schizophrenia. *Biol Psychiat* 1997;41:43–49. [PubMed: 8988794]
76. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. *Psychiatr Clin North Am* 1993;16(2):295–312. [PubMed: 8332566]
77. Goldberg TE, Karson CN, Leleszi JP, Weinberger DR. Intellectual impairment in adolescent psychosis: a controlled psychometric study. *Schizophr Res* 1988;1:261–266. [PubMed: 3154512]
78. Goldberg TE, Ragland D, Torrey F, Gold JM, Bigelow LB, Weinberger DR. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. *Arch Gen Psychiatry* 1990;47:1066–1072. [PubMed: 2241508]
79. Goldberg TE, Gold JM, Greenberg R, Griffin A, Schulz C, Pickar D, Kleinman JE, Weinberger DR. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. *Am J Psychiatry* 1993;150:1355–1362. [PubMed: 8352346]
80. Baxter RD, Liddle PF. Neuropsychological deficits associated with schizophrenic syndromes. *Schizophr Res* 1998;30:239–249. [PubMed: 9589518]
81. Moritz S, Andresen B, Jacobsen D, Mersmann K, Wilke U, Lambert M, Naber D, Krausz M. Neuropsychological correlates of schizophrenic syndromes in patients treated with atypical neuroleptics. *Eur Psychiatry* 2001;16:354–361. [PubMed: 11585716]
82. Nieuwenstein MR, Aleman A, de Haan EHF. Relationship between symptoms dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. *J of Psychiatric Res* 2001;35:119–125.
83. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. *Am J Psychiatry* 1999;156:1358–1366. [PubMed: 10484945]
84. Liddle PF, Morris DL. Schizophrenic syndromes and frontal lobe performance. *Br J Psychiatry* 1991;158:340–345. [PubMed: 2036532]
85. Moritz S, Heeren D, Andresen B, Krausz M. An analysis of the specificity and the syndromal correlates of verbal memory impairments in schizophrenia. *Psychiatry Res* 2001;101(1):23–31. [PubMed: 11223116]

86. O'Leary DS, Flaum M, Kessler ML, Flashman LA, Arndt S, Andreasen NC. Cognitive correlates of the negative disorganized and psychotic symptom dimensions of schizophrenia. *J Neuropsychiatry Clin Neurosci* 2000;12:4–15. [PubMed: 10678506]
87. Weinberger DR, Berman KF, Zec RF. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. I: regional cerebral blood flow (rCBF) evidence. *Arch Gen Psychiatry* 1986;43:114–125. [PubMed: 3947207]
88. Andreasen NC, Flaum M, Arndt S. The comprehensive assessment of symptoms and history (CASH): an instrument for assessing psychopathology and diagnosis. *Arch Gen Psychiatry* 1992;49:615–623. [PubMed: 1637251]
89. Schuepbach D, Merlo MCG, Goenner F, Staikov I, Mattle HP, Kierks T, Brenner HD. Cerebral hemodynamic response induced by the Tower of Hanoi puzzle and the Wisconsin Card Sorting Test. *Neuropsychologia* 2002;40:39–53. [PubMed: 11595261]
90. Schuepbach D, Bader JP, Hell D, Baumgartner RW. Cerebral hemodynamics and processing speed during category learning. *NeuroReport* 2004;15:1195–1198. [PubMed: 15129173]
91. Schuepbach D, Hell D, Baumgartner RW. Lateralization of cerebral hemodynamics during Wisconsin Card Sorting Test: a functional transcranial Doppler sonography study. *Clin Neurophysiol* 2005;116:1041–1048. [PubMed: 15826844]
92. Frauenfelder BA, Schuepbach D, Baumgartner RW, Hell D. Specific alterations of cerebral hemodynamics during a planning task: a transcranial Doppler sonography study. *Neuroimage* 2004;22:1223–1230. [PubMed: 15219594]
93. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. *Schizophr Res* 2001;49:1–52. [PubMed: 11343862]
94. Kelsoe JR, Cadet JL, Pickar D, Weinberger DR. Quantitative neuroanatomy in schizophrenia. *Arch Gen Psychiatry* 1988;45:533–541. [PubMed: 3377640]
95. Mathew RJ, Partrain CL, Prakash R, Kulkarni MV, Logan TP, Wilson WH. A study of the septum pellucidum and corpus callosum in schizophrenia with MR imaging. *Acta Psychiatr Scand* 1985;72:414–421. [PubMed: 4091025]
96. McCarley RW, Wible CG, Frumin M, Hirayasu Y, Levitt JJ, Fischer IA, Shenton ME. MRI anatomy of schizophrenia. *Biol Psychiatry* 1999;45(9):1099–1119. [PubMed: 10331102]
97. Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G, Stuart GW, Yung A, Phillips L, McGorry PD. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. *Schiz Bulletin* 2005;31(3):672–696.
98. Mitropoulou V, Goodman M, Sevy S, Elman I, New AS, Iskander EG, Silverman JM, Breier A, Siever LJ. Effects of acute metabolic stress on the dopaminergic and pituitary—adrenal axis activity in patients with schizotypal personality disorder. *Schiz Research* 2004;70:27–31.
99. Catafau AM, Parellada E, Lomeña FJ, Bernardo M, Pavía J, Ros D, Setoain J, Gonzalez-Monclús E. Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO-SPECT patterns in your neuroleptic naïve patients with acute disease. *J Nucl Med* 1994;35(6):935–941. [PubMed: 8195878]
100. Hoyer S, Österreich K. Blood flow and oxidative metabolism of the brain in patients with schizophrenia. *Psychiatria Clin* 1975;8:304–313.
101. Owega A, Klingelhöfer J, Sabir O, Kunert HJ, Albers M, Saß H. Cerebral blood flow velocity in acute schizophrenic patients: a transcranial Doppler ultrasonography study. *Stroke* 1998;29:1149–1154. [PubMed: 9626287]
102. Brodie JD, Christman DR, Corona JF, Fowler JS, Gomez-Mont F, Jaeger J, Micheels PA, Rotrosen J, Russell JA, Volkow ND, et al. Patterns of metabolic activity in the treatment of schizophrenia. *Ann Neurol* 1984;15:166–169.
103. Lewis SW, Ford RA, Syed GM, Reveley AM, Toone BK. A controlled study of Tc-99m-HMPAO single-photon emission imaging in chronic schizophrenia. *Psychol Med* 1992;22(1):27–35. [PubMed: 1574564]
104. Wolkin A, Jaeger J, Brodie JD, Wolf AP, Fowler J, Rotrosen J, Gomez-Mont F, Cancro R. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. *Am J Psychiatry* 1985;142(5):564–571. [PubMed: 3872603]

105. Paulman RG, Devous MD Sr, Gregory RR, Herman JH, Jennings L, Bonte FJ, Nasrallah HA, Raese JD. Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function. *Biol Psychiatry* 1990;27:377–399. [PubMed: 2106922]
106. Kessler, RC. Epidemiology of psychiatric comorbidity. In: Tsuang, MT.; Tohen, M.; Zahner, GEP., editors. *Textbook of Psychiatric Epidemiology*. Wiley-Liss; New, NY: 1995.
107. Negrete JC. Clinical aspects of substance abuse in persons with schizophrenia. *Can J Psychiatry* 2003;18:14–21. [PubMed: 12635559]
108. Jablensky A, McGrath J, herman H, Castle D, Gureje O, Evans M, Carr V, Morgan V, Korten A, Harvey C. Psychotic disorders in urban areas: an overview of the study of low prevalence disorders. *Aust N Z J Psychiatry* 2003;34:221–236. [PubMed: 10789527]
109. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) Study. *JAMA* 1990;264(19):2511–2518. [PubMed: 2232018]
110. Carey MP, Carey KB, Meisler AW. Psychiatric symptoms in mentally ill chemical abusers. *Journal of Nervous and Mental Disease* 1991;179:136–138. [PubMed: 1997660]
111. Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, Ombao H, Kupfer DJ. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. *J Clin Psychiatry* 2002;63:528–533. [PubMed: 12088166]
112. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. *Am J Psychiatry* 2003;160:112–117. [PubMed: 12505809]
113. Sharma R, Marker HR. Mortality in affective disorder. *J Affect Disord* 1994;31:91–96. [PubMed: 8071480]
114. Sharma, R.; Marker, HR.; Ballenger, JC. Mortality in affective disorder. In: Talbott, JA., editor. *Year Book of Psychiatry and Applied Mental Health*. Mosby Year Book, Inc; Chicago, Ill: 1996.
115. D'Souza DC, Abi-Saab WM, Madonick S, et al.  $\Delta 9$ -tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis and addiction. *Biol Psychiatry* 2005;57:594–608. [PubMed: 15780846]
116. Sevy S, Kay SR, Opler L, van Praag HM. Significance of cocaine history in schizophrenia. *J Nerv Ment Dis* 1990;178:642–648. [PubMed: 2230749]
117. Halikas JA, Goodwin DW, Guze SB. Marijuana use and psychiatric illness. *Arch Gen Psychiatry* 1972;27:162–165. [PubMed: 5042824]
118. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. *Br J Psychiatry* 2005;187:9–20. [PubMed: 15994566]
119. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. *Pharmacol Biochem Behav* 1997;56:803–807. [PubMed: 9130308]
120. Maccarone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D, Bernardi G, Finazzi-Agro A, Calabresi P. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. *J Neurochem* 2003;85:1018–1025. [PubMed: 12716433]
121. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nat Neurosci* 1999;2(4):358–363. [PubMed: 10204543]
122. Rodríguez de Fonseca F, Del Arco I, Martín-Calderón JL, Gorriti MA, Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. *Neurobiol Dis* 1998;5:483–501. [PubMed: 9974180]
123. Sherman, C. Lithium displays impressive antisuicidal effects. *Clinical Psychiatry News*. 2001. [http://findarticles.com/p/articles/mi\\_hb4345/is\\_10\\_29/ai\\_n28870181](http://findarticles.com/p/articles/mi_hb4345/is_10_29/ai_n28870181)
124. Gearon JS, Bellack AS. Addiction services: women with schizophrenia and co-occurring substance use disorders: an increased risk for violent victimization and HIV. *Community Mental Health Journal* 1999;35(5):401–419. [PubMed: 10547116]
125. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. *BR J of Psychiatry* 2005;187:306–313. [PubMed: 16199787]

126. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. *Schizophrenia Research* 1999;35:93–100.
127. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. *Am J Epidemiol* 2002;156(4):319–327. [PubMed: 12181101]
128. Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, Arnold LM, Amicone J. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. *Arch Gen Psychiatry* 2007;64:57–64. [PubMed: 17199055]
129. El-Mallakh RS, Brown C. The effect of extreme marijuana use on the long-term course of bipolar illness: a single case study. *Journal of Psychoactive Drugs* 2007;39(2):201–202. [PubMed: 17703715]
130. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. *Journal of Psychoactive Drugs* 1998;30:171–177. [PubMed: 9692379]
131. Gruber JA, Pope HG Jr, Brown ME. Do patients use marijuana as an antidepressant? *Depression* 1996;4:77–80. [PubMed: 9160645]
132. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. *Br J Psychiatry* 2005;187:9–20. [PubMed: 15994566]
133. Dixon L, Haas G, Weiden P, Sweeney J, Francis A. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. *Schizophr Bull* 1990;16:69–79. [PubMed: 2185536]
134. Addington J, Addington D. Substance abuse and cognitive functioning in schizophrenia. *J Psychiatry Neurosci* 1997;22:99–104. [PubMed: 9074303]
135. Addington J, Duchak V. Reasons for substance use in schizophrenia. *Acta Psychiatr Scand* 1997;96:329–333. [PubMed: 9395149]
136. Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, Arnold LM, Amicone J. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. *Arch Gen Psychiatry* 2007;64:57–64. [PubMed: 17199055]
137. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. *Schizophrenia Research* 1999;35:93–100.
138. Liraud F, Veroud H. Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. *Encephale* 2002;28:160–168. [PubMed: 11972143]
139. Pencer A, Addington J. Substance use and cognition in early psychosis. *J Psychiatry Neurosci* 2003;28:48–54. [PubMed: 12587850]
140. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts neurocognition at 10-year follow-up. *Schizophr Res* 2005;75:135–137. [PubMed: 15820332]
141. Jockers-Scherübl MC, Wolf T, Radzei N, et al. Cannabis induces different cognitive changes schizophrenic patients and healthy controls. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31:1054–1063. [PubMed: 17482741]
142. Sevy S, Burdick KE, Visweswarajah H, Abdelmessih S, Lukin M, Yechiam E, Bechara A. Iowa Gambling Task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. *Schizophr Res* 2007;92:74–84. [PubMed: 17379482]
143. Cahill CM, Malhi GS, Ivanovski B, Lagopoulos J, Cohen M. Cognitive compromise in bipolar disorder with chronic cannabis use: cause or consequence? *Expert Rev. Neurotherapeutics* 2006;6(4):591–598.
144. Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce H, Napolitano B, Bilder RM. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. *Br J of Psychiatry* 2007;190:230–236. [PubMed: 17329743]
145. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia—a region of interest, voxel based morphometric study. *Schizophr Res* 2008;99:1–6. [PubMed: 18248793]

146. Rais M, Cahn W, Van Haren N, Schnack H, Caspers E, Hulshoff Pol H, Kahn R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. *Am J Psychiatry* 2008;165:490–496. [PubMed: 18281413]
147. Jockers-Scherübl MC, Matthies U, Danker-Hopfe H, Lang UE, Mahlberg R, Hellweg R. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naïve schizophrenic patients. *J of Psychopharmacol* 2003;17(4):439–445. [PubMed: 14870957]
148. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis and psychosis. *Drug Alcohol Depend* 2003;71:37–48. [PubMed: 12821204]
149. Medina KL, Nagel BJ, Park A, McQueeney T, Tapert S. Depressive symptoms in adolescents: associations with white matter volume and marijuana use. *Journal of Child Psychology and Psychiatry* 2007;48(6):592–600. [PubMed: 17537075]
150. Depp C, Lebowitz BD. Clinical trials: bridging the gap between efficacy and effectiveness. *International Review of Psychiatry* 2007;19(5):531–539. [PubMed: 17896233]
151. Donovan SJ, Nunes EV. Treatment of comorbid affective and substance use disorders: therapeutic potential of anticonvulsants. *The American Journal of Addictions* 1998;7(3):210–220.
152. Rousaville BJ. *DSM-V* Research agenda: substance abuse/psychosis comorbidity. *Schizophrenia Bulletin* 2007;33(4):947–952. [PubMed: 17556751]
153. Havassay BE, Alvidrez J, Owen KK. Comparisons of patients with comorbid psychiatric and substance use disorders: implication for treatment and service delivery. *Am J Psychiatry* 2004;161(1):139–145. [PubMed: 14702262]
154. Cadet JL, Bolla K, Herning RI. Neurological assessment of marijuana users. *Methods Mol Med* 2006;123:255–268. [PubMed: 16506413]